Supporting The Front Line of Our Freedom January 8, 2016 • admin • Working to better protect our military personnel from chemical nerve agent attack. Related News Countervail receives additional $630,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. August 3, 2015 Incorporation of Countervail June 20, 2007
